Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 1997

View Archived Issues

Company Profile: Elan

Novo Nordisk develops A1 agonist with neuroprotectant activity

Efficacy of TxA2 antagonist in IBD established

New muscarinic compound from Wyeth-Ayerst

TheraTech: Q3 1997 highlights

ImClone Systems: Q3 1997 highlights

Pfizer improves on NMDA antagonists

Promising results reported from pilot trial of Repel

Enzon: Q1 1998 highlights

New antihyperalgesic agents from Adolor

NPS and SmithKline Beecham sign additional extension of osteoporosis agreement

Novel valproic acid prodrug reported at scientific meeting

Preclinical profile of Novartis' dermatology candidate

AMPA antagonist investigated for treatment of drug withdrawal

Safe and effective new D2 partial agonist in development at Wyeth-Ayerst

Alteon prepares new AGE inhibitors

CRF antagonists from DuPont Merck for anxiety, depression and related disorders

Lilly discovers highly potent and selective NPY Y1 receptor antagonists

Adefovir dipivoxil now available in expanded access program

Seragen submits BLA for CTCL biological product

Novel liver-targeted conjugate for hepatitis B virus infection

Preclinical toxicity profile of ISIS-2503

BioTime reports preliminary phase III data from Hextend trial

FDA approves shorter treatment claim for Mentax

Boehringer Mannheim returns to PDL rights to two antiviral compounds

StressGen prepares to evaluate Oncocine in clinical trials

FDA advisory committee recommends approval of TOBI

Propecia recommended for approval for hair loss in men

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...